Opinion|Videos|January 23, 2025 (Updated: January 23, 2025)

Abiraterone Acetate Versions for Treatment of mCRPC

Author(s)Jose De La Cerda III, MD, MPH

This video segment explores how to choose between the original brand, generic, and micronized versions of abiraterone, considering factors like efficacy, cost, patient preference, and clinical context.

Episodes in this series

EP. 1 Bone Predominant mCRPC Patient Case

EP. 1 Bone Predominant mCRPC Patient Case

EP. 2 Case 1: A 68-Year-Old Man with Bone-Predominant Metastatic Castration-Resistant Prostate Cancer (mCRPC)

EP. 2 Case 1: A 68-Year-Old Man with Bone-Predominant Metastatic Castration-Resistant Prostate Cancer (mCRPC)

EP. 3 Abiraterone Acetate Versions for Treatment of mCRPC

EP. 3 Abiraterone Acetate Versions for Treatment of mCRPC

EP. 4 Patient Selection Criteria for Different Versions of Abiraterone Acetate in mCRPC

EP. 4 Patient Selection Criteria for Different Versions of Abiraterone Acetate in mCRPC

EP. 5 Assessing Treatment Efficacy: Communication with Patients and Caregivers

EP. 5 Assessing Treatment Efficacy: Communication with Patients and Caregivers

EP. 6 Patient with mCRPC and Hepatic Disease

EP. 6 Patient with mCRPC and Hepatic Disease

EP. 7 Treatment and Co-Management of mCRPC Patients with Aggressive Disease

EP. 7 Treatment and Co-Management of mCRPC Patients with Aggressive Disease

Video content above is prompted by the following:

Abiraterone is now available as the original brand, generic and micronized versions. How do you choose between these different options of abiraterone?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Precision Medicine and Patient Selection in mHSPC

ByScott Sellinger, MD, FACS

August 20th 2026

Bringing POTOMAC Data Into Community Urology Practice for High-Risk NMIBC

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 19th 2026

POTOMAC Subgroup Data: Cystectomy Risk and Rare Adverse Events in NMIBC

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 19th 2026

Managing Immune-Related Adverse Events With Durvalumab Plus BCG in NMIBC

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 19th 2026

Inside the POTOMAC Trial: Durvalumab Plus BCG for High-Risk NMIBC

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 19th 2026

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery

Trial launches of molecular glue degrader plus apalutamide in mCRPC